Search

Displaying results 1361 - 1370 of 2160 in total
  1. Drug

    Eldecalcitol

    go.drugbank.com/drugs/DB05295
    Investigational

    Eldecalcitol (ED-71), a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis.

  2. Drug

    Tauroursodeoxycholic acid

    go.drugbank.com/drugs/DB08834
    ApprovedInvestigationalWithdrawn

    Tauroursodeoxycholic acid, also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid that is produced in humans at a low concentration. It is a taurine conjugate of ursodeoxycholic acid with comparable therapeutic effi...

  3. Drug

    Efmoroctocog alfa

    go.drugbank.com/drugs/DB11607
    ApprovedInvestigational

    Efmoroctocog alfa is a fully recombinant factor VIII-Fc fusion protein (rFVIIIFc) with an extended half-life compared with conventional factor VIII (FVIII) preparations, including recombinant FVIII (rFVIII) products such as DB13999 . It ...

  4. Drug

    Navamepent

    go.drugbank.com/drugs/DB21096
    Investigational

    Navamepent is under investigation in clinical trial NCT02329743 (Efficacy and Safety of RX-10045 Ophthalmic Solution for Ocular Inflammation and Pain in Cataract Surgery).

  5. Drug

    Betaprodine

    go.drugbank.com/drugs/DB01473
    ExperimentalIllicit

    (From Martindale, The Extra Pharmacopoeia, 30th ed, p1067)

  6. Drug

    NGX267

    go.drugbank.com/drugs/DB05152
    Investigational

    NGX267 is a muscarinic agonist. It is developed for the treatment of Alzheimer’s disease and has shown the potential to both reduce symptoms and slow disease progression.

  7. Drug

    Carotuximab

    go.drugbank.com/drugs/DB06322
    Investigational

  8. Drug

    Glucose-6-Phosphate

    go.drugbank.com/drugs/DB03581
    Experimental

    (Stedman, 26th ed)

  9. Drug

    D-Asparagine

    go.drugbank.com/drugs/DB03943
    Experimental

    (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed)

  10. Drug

    Lomitapide

    go.drugbank.com/drugs/DB08827
    Approved

    Lomitapide, marketed under the brand names Juxtapid (USA) and Lojuxta (EU), is a first-in-class, small-molecule inhibitor of microsomal triglyceride transfer protein (MTP).